

Special Issue

Recent Advances in Diagnosis, Therapeutics, and Mechanistic Research of Multiple Myeloma

Message from the Guest Editor

Multiple myeloma (MM), a malignant plasma cell disorder, remains a significant challenge in hematological oncology. Despite the fact that remarkable advancements in treatment strategies have been made in recent decades, including the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, MM is largely considered an incurable disease due to the inevitable development of drug resistance and disease relapse. This Special Issue aims to compile a collection of high-quality original research articles and comprehensive reviews that highlight the cutting-edge progress made across the entire spectrum of MM management. We seek to shed light on novel insights into disease biology, the development of more precise diagnostic tools, and the emergence of innovative therapeutic modalities that are reshaping the clinical landscape. We invite contributions that address, but are not limited to, diagnostic advances, therapeutic innovations, and mechanistic research. This Special Issue will serve as a valuable resource for clinicians and researchers dedicated to conquering multiple myeloma. We look forward to receiving your impactful contributions.

Guest Editor

Dr. Xiaqing Dong

Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,
Nanjing University, Nanjing, China

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/256587

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).